

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau



WIPO | PCT



(10) International Publication Number
WO 2013/134085 A8

(43) International Publication Date
12 September 2013 (12.09.2013)

(51) International Patent Classification:

C07D 235/02 (2006.01) *C07C 49/323* (2006.01)
C07D 403/06 (2006.01) *A61K 31/4184* (2006.01)
C07D 407/06 (2006.01) *A61P 25/28* (2006.01)

(21) International Application Number:

PCT/US2013/028796

(22) International Filing Date:

4 March 2013 (04.03.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/606,786 5 March 2012 (05.03.2012) US

(71) Applicants: **BOEHRINGER INGELHEIM INTERNATIONAL GMBH** [DE/DE]; Binger Strasse 173, 55216 Ingelheim Am Rhein (DE). **VITAE PHARMACEUTICALS, INC.** [US/US]; 502 West Office Center Drive, Fort Washington, PA 19034 (US).

(72) Inventors: **BUKHTIYAROV, Yuri**; 1116 Belvedere Drive, Boothwyn, PA 19061 (US). **CACATIAN, Salvacion**; 169 Front Street, Conshohocken, PA 19428 (US). **DILLARD, Lawrence, Wayne**; 496 Kings Road, Yardley, PA 19067 (US). **DORNER-CIOSSEK, Cornelia**; Boehringer Ingelheim Gmbh, Corporate Patents, Binger Strasse 173, 55216 Ingelheim Am Rhein (DE). **FUCHS, Klaus**; Boehringer, Ingelheim Gmbh, Corporate Patents, Binger Strasse 173, 55216 Ingelheim Am Rhein (DE). **JIA, Lanqi**; 22 Beaver Hill Road, Horsham, PA 19044 (US). **LALA, Deepak, S.**; 1619 Kellogg Drive, Lower Gwynedd, PA 19002 (US). **MORALES-RAMOS, Angel**; 2310 Buckeye Circle, Blue Bell, PA 19422 (US). **RAST, Georg**; Boehringer Ingelheim Gmbh, Corporate Patents, Binger Strasse 173, 55216 Ingelheim Am Rhein (DE). **REEVES, Jonathan**; c/o VP, IP, Legal, Boehringer Ingelheim Usa Corp., 900 Ridgebury Road, P.O. Box 368, Ridgefield, CT 06877-0368 (US). **SINGH, Suresh, B.**; 4 Adams Road, Kendall Park, NJ 08824 (US). **VENKATRAMAN, Shankar**; 114 Country Lane, Lansdale, PA 19446 (US). **XU, Zhenrong**; 3224 Riding Court, Chalfont, PA 18914 (US). **YUAN, Jing**; 537 Candlemaker Way, Lansdale, PA 19446 (US). **ZHAO, Yi**; 1025 East Avenue, Blue Bell, PA

19422 (US). **ZHENG, Yajun**; 605 Giffin Court, Hockessin, DE 19707 (US).

(74) Agents: **DAVIS, Steven, G.** et al.; McCarter & English, LLP, 265 Franklin Street, Boston, MA 02110 (US).

(81) Designated States (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(48) Date of publication of this corrected version:

4 September 2014

(15) Information about Correction:

see Notice of 4 September 2014

(54) Title: INHIBITORS OF BETA-SECRETASE

(57) Abstract: The present invention relates to spirocyclic acylguanidines and their use as inhibitors of the β -secretase enzyme (BACE1) activity, pharmaceutical compositions containing the same, and methods of using the same as therapeutic agents in the treatment of neurodegenerative disorders, disorders characterized by cognitive decline, cognitive impairment, dementia and diseases characterized by production of β -amyloid aggregates.



WO 2013/134085 A8